Tag Archives: venture

Hot Life Science Investor Mandate 1: Single Family Office Seeking Global Opportunities in Brain Health

10 Jul

A Single Family Office based in the western United States makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million.  The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania.

The firm focuses on brain health, with 80% of the fund’s investments occurring in this indication area.  The firm’s mandate encompasses both diseases of the nervous system and psychiatric disorders, with a particular interest in Alzheimer’s disease.  The firm is open to investing in therapeutics, diagnostics and medical devices, and is interested in interdisciplinary approaches.  The firm seeks early-stage opportunities, but will also consider later-stage opportunities.  The firm’s prior investments include drug discovery for treatments for Alzheimer’s disease, and novel diagnostics including a tool that tracks early cognitive decline.

The firm strongly prefers to invest in privately held companies.  The firm only backs top scientists pursuing breakthrough approaches, and does not invest in “me-too” ideas.  In the medical technology sector the firm prefers to invest in companies developing platform technologies with multiple potential applications.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: Venture Arm Focuses on Companies Developing New Drugs, Devices

31 Oct

The corporate venture arm of a larger foundation based in Europe has approximately $35 billion in AUM, provides (equity only) seed and venture capital to development stage companies, and also takes significant ownership positions in well-established companies within life science and biotechnology.

The firm will invest at any stage of development – seed, venture, and growth. They also make late-stage investments in public/private companies with a positive cash flow, and can allocate up to $40M or more depending on specific cases, but generally allocate between $5M and $20M. The firm seeks companies that are based in North America and Europe, but has no current mandate for the number of allocations it plans to make.

The venture arm is opportunistic in the life sciences space. Specifically, they focus on companies that specialize in the development of new drugs, new procedures for diagnosis and control of diseases, development of medical devices and instruments, and industrial biotechnology. They are very opportunistic in terms of subsectors and indications.

Currently, this particular firm is active in companies developing therapeutics and diagnostics targeting cardiovascular diseases, infectious diseases, immune disorders, diseases of the nervous system, mental and behavioral disorders, and cancer. Additionally, they have invested in companies developing therapeutics based on small molecules and antibodies. The firm has also made venture investments in companies developing medical technology in the area of reusable instruments, wound care, single use devices, therapeutic radiation devices, and active implantable devices.

 

%d bloggers like this: